Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery

Xenobiotica

Volumn 42, Issue 9, 2012, Pages 917-928

  Thörn, Helena Anna ^a   Yasin, Mohammed ^b   Dickinson, Paul Alfred ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

first pass metabolism; glucuronidation; intestinal metabolism; pigs; Raloxifene

Indexed keywords

ATROPINE; DEXTRAN; DRUG METABOLITE; KETAMINOL; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM BROMIDE; RALOXIFENE; RALOXIFENE 4' BETA GLUCURONIDE; TILETAMINE; TILETAMINE PLUS ZOLAZEPAM; UNCLASSIFIED DRUG; XYLAZINE; ZOLAZEPAM;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PORTAL VEIN; SAMPLING; SINGLE DRUG DOSE; SWINE; VENOUS BLOOD;

EID: 84864989996     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.683497     Document Type: Article

References (35)

1. Achour B, Barber J, Rostami-Hodjegan A. (2011). Cytochrome p450 pig liver pie: Determination of individual cytochrome p450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectroscopy. Drug Metab Dispos 39:2130-2134.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
3. Anzenbacher P, Soucek P, Anzenbacherova E, Gut I, Hruby K, Svoboda Z, Kvetina J. (1998). Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 26:56-59.
4. Benet LZ, Broccatelli F, Oprea TI. (2011). BDDCS applied to over 900 drugs. AAPS J 13:519-547.
5. Bernard O, Guillemette C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
6. Bowalgaha K, Miners JO. (2001). The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
7. Cassidy MK, Houston JB. (1980). In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol. J Pharm Pharmacol 32:57-59.
8. Cassidy MK, Houston JB. (1984). In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metab Dispos 12:619-624.
9. Cubitt HE, Houston JB, Galetin A. (2009). Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
10. Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: Integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864-873.
11. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, Obach RS. (2008). Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260-2271.
12. Desille M, Corcos L, L'Helgoualc'h A, Fremond B, Campion JP, Guillouzo A, Clement B. (1999). Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation 68:1437-1443.
13. Jeong EJ, Lin H, Hu M. (2004). Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310:376-385.
14. Jeong EJ, Liu Y, Lin H, Hu M. (2005). Species- and disposition modeldependent metabolism of raloxifene in gut and liver: Role of UGT1A10. Drug Metab Dispos 33:785-794.
15. Kararli TT. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
16. Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
17. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T. (2011). Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39:1495-1502.
18. Lundahl A, Hedeland M, Bondesson U, Lennernas H. (2011). In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5a-reductase inhibitor finasteride and the effects of coadministered ketoconazole. Drug Metab Dispos 39:847-857.
19. Miners JO, Knights KM, Houston JB, Mackenzie PI. (2006). In vitroin vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochem Pharmacol 71:1531-1539.
20. Mistry M, Houston JB. (1985). Quantitation of extrahepatic metabolism. Pulmonary and intestinal conjugation of naphthol. Drug Metab Dispos 13:740-745.
21. Mistry M, Houston JB. (1987). Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710-717.
22. Mizuma T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140-141.
23. Myers MJ, Farrell DE, Howard KD, Kawalek JC. (2001). Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 29:908-915.
24. Nordgren A, Karlsson T, Wiklund L. (2002). Glutamine concentration and tissue exchange with intravenously administered alphaketoglutaric acid and ammonium: A dose-response study in the pig. Nutrition 18:496-504.
25. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernas H. (2006). First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189.
26. Raoof AA, Van Obbergh LJ, De Ville De Goyet J, Verbeeck RK. (1996). Extrahepatic glucuronidation of propofol in man: Possible contribution of gut wall and kidney. Eur J Clin Pharmacol 50:91-96.
27. Soucek P, Zuber R, Anzenbacherova E, Anzenbacher P, Guengerich FP. (2001). Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 1:11.
28. Szotakova B, Baliharova V, Lamka J, Nozinova E, Wsol V, Velik J, Machala M, Neca J, Soucek P, Susova S, Skalova L. (2004). Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci 76:43-51.
29. Thorn HA, Hedeland M, Bondesson U, Knutson L, Yasin M, Dickinson P, Lennernas H. (2009). Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: Important for the mechanistic understanding of first-pass drug-drug interactions. Drug Metab Dispos 37:2186-2196.
30. Thorn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernas H. (2011). Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 43:89-98.
31. Trdan T, Roŝkar R, Trontelj J, Ravnikar M, Mrhar A. (2011). Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 879:2323-2331.
32. Trontelj J, Bogataj M, Marc J, Mrhar A. (2007). Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 855:220-227.
33. Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDPglucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
34. Watanabe Y, Nakajima M, Yokoi T. (2002). Troglitazone glucuronidation in human liver and intestine microsomes: High catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469.
35. Veroli P, O'Kelly B, Bertrand F, Trouvin JH, Farinotti R, Ecoffey C. (1992). Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 68:183-186.